litlas
Log inCreate account

David A. Luckenbaugh

Active 1998–2020

89
Papers
21,287
Citations
81
h-index
87
i10-index

Citations

Citations per year for David A. Luckenbaugh1990: 1 citations1997: 1 citations1998: 1 citations2000: 2 citations2001: 7 citations2002: 16 citations2003: 36 citations2004: 40 citations2005: 91 citations2006: 165 citations2007: 184 citations2008: 240 citations2009: 296 citations2010: 245 citations2011: 286 citations2012: 340 citations2013: 396 citations2014: 378 citations2015: 477 citations2016: 328 citations2017: 283 citations2018: 314 citations2019: 674 citations2020: 790 citations2021: 622 citations2022: 493 citations2023: 309 citations2024: 449 citations2025: 187 citations2026: 1 citations1991–1996: no citations, so these years are not shown1999: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,302 citing papers, 32.4% of this breakdownUnited Kingdom: 485 citing papers, 6.8% of this breakdownCanada: 478 citing papers, 6.7% of this breakdownChina: 443 citing papers, 6.3% of this breakdownGermany: 349 citing papers, 4.9% of this breakdownItaly: 274 citing papers, 3.9% of this breakdownAustralia: 212 citing papers, 3% of this breakdownNetherlands: 208 citing papers, 2.9% of this breakdownBrazil: 196 citing papers, 2.8% of this breakdownJapan: 191 citing papers, 2.7% of this breakdownSpain: 184 citing papers, 2.6% of this breakdownFrance: 179 citing papers, 2.5% of this breakdown
0%32.4%Other 22.5%

Institutions

Fields

  • Medicine49.9%
  • Neuroscience35%
  • Psychology9.4%
  • Biochemistry, Genetics and Molecular Biology3.5%
  • Computer Science0.6%
  • Health Professions0.3%
  • Other1.3%

Topics

  • Treatment of Major Depression14.1%
  • Tryptophan and brain disorders11.6%
  • Bipolar Disorder and Treatment6.7%
  • Neuroscience and Neuropharmacology Research5.5%
  • Stress Responses and Cortisol4.4%
  • Neurotransmitter Receptor Influence on Behavior4.4%
  • Other53.3%

Coauthors

All papers

Open in search
  1. A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression

    Authors: Carlos A. Zarate, Jaskaran Singh, Paul J. Carlson, Nancy E. Brutsché, Rezvan Ameli, David A. Luckenbaugh, Dennis S. Charney, Husseini K. Manji - Archives of General Psychiatry 2006 cited by 3,753

  2. A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression

    Authors: Nancy Diazgranados, Lobna Ibrahim, Nancy E. Brutsché, Andrew B. Newberg, Phillip D. Kronstein, Sami Khalife, William Kammerer, Zenaide Quezado, David A. Luckenbaugh, Giacomo Salvadore, Rodrigo Machado‐Vieira, Husseini K. Manji, Carlos A. Zarate - Archives of General Psychiatry 2010 cited by 969

  3. Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial

    Authors: Carlos A. Zarate, Nancy E. Brutsché, Lobna Ibrahim, Jose Franco‐Chaves, Nancy Diazgranados, Anibal Cravchik, Jessica Selter, Craig A. Marquardt, Victoria Liberty, David A. Luckenbaugh - Biological Psychiatry 2012 cited by 817

  4. Do the dissociative side effects of ketamine mediate its antidepressant effects?

    Authors: David A. Luckenbaugh, Mark J. Niciu, Dawn F. Ionescu, Neal M. Nolan, Erica M. Richards, Nancy E. Brutsché, Sara Guevara, Carlos A. Zarate - Journal of Affective Disorders 2014 cited by 282

  5. Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder

    Authors: Nancy Diazgranados, Lobna Ibrahim, Nancy E. Brutsché, Rezvan Ameli, Ioline D. Henter, David A. Luckenbaugh, Rodrigo Machado‐Vieira, Carlos A. Zarate - The Journal of Clinical Psychiatry 2010 cited by 563

  6. Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression

    Authors: Mark J. Niciu, Bridget Shovestul, Brittany A. Jaso, Cristan Farmer, David A. Luckenbaugh, Nancy E. Brutsché, Lawrence T. Park, Elizabeth D. Ballard, Carlos A. Zarate - Journal of Affective Disorders 2018 cited by 133

  7. Relationship of Ketamine's Plasma Metabolites with Response, Diagnosis, and Side Effects in Major Depression

    Authors: Carlos A. Zarate, Nancy E. Brutsché, Gonzalo Laje, David A. Luckenbaugh, Swarajya Lakshmi Vattem Venkata, Anuradha Ramamoorthy, Ruin Moaddel, Irving W. Wainer - Biological Psychiatry 2012 cited by 283

  8. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression

    Authors: Níall Lally, Allison C. Nugent, David A. Luckenbaugh, Rezvan Ameli, Jonathan P. Roiser, Carlos A. Zarate - Translational Psychiatry 2014 cited by 266

  9. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine

    Authors: Níall Lally, Allison C. Nugent, David A. Luckenbaugh, Mark J. Niciu, Jonathan P. Roiser, Carlos A. Zarate - Journal of Psychopharmacology 2015 cited by 223

  10. A Double-Blind, Placebo-Controlled Study of Memantine in the Treatment of Major Depression

    Authors: Carlos A. Zarate, Jaskaran Singh, Jorge A. Quiroz, Georgette De Jesus, Kirk K. Denicoff, David A. Luckenbaugh, Husseini K. Manji, Dennis S. Charney - American Journal of Psychiatry 2006 cited by 380

  11. Early-Onset Bipolar Disorder and Treatment Delay Are Risk Factors for Poor Outcome in Adulthood

    Authors: Robert M. Post, Gabriele S. Leverich, Ralph Kupka, Paul E. Keck, Susan L. McElroy, Lori L. Altshuler, Mark A. Frye, David A. Luckenbaugh, Michael Rowe, Heinz Grunze, Trisha Suppes, Willem A. Nolen - The Journal of Clinical Psychiatry 2010 cited by 361

  12. Improvement in suicidal ideation after ketamine infusion: Relationship to reductions in depression and anxiety

    Authors: Elizabeth D. Ballard, Dawn F. Ionescu, Jennifer L. Vande Voort, Mark J. Niciu, Erica M. Richards, David A. Luckenbaugh, Nancy E. Brutsché, Rezvan Ameli, Maura L. Furey, Carlos A. Zarate - Journal of Psychiatric Research 2014 cited by 285

  13. Course of Improvement in Depressive Symptoms to a Single Intravenous Infusion of Ketamine vs Add-on Riluzole: Results from a 4-Week, Double-Blind, Placebo-Controlled Study

    Authors: Lobna Ibrahim, Nancy Diazgranados, Jose Franco‐Chaves, Nancy E. Brutsché, Ioline D. Henter, Phillip D. Kronstein, Ruin Moaddel, Irving W. Wainer, David A. Luckenbaugh, Husseini K. Manji, Carlos A. Zarate - Neuropsychopharmacology 2012 cited by 310

  14. Effect of Baseline Anxious Depression on Initial and Sustained Antidepressant Response to Ketamine

    Authors: Dawn F. Ionescu, David A. Luckenbaugh, Mark J. Niciu, Erica M. Richards, Elizabeth E. Slonena, Jennifer L. Vande Voort, Nancy E. Brutsché, Carlos A. Zarate - The Journal of Clinical Psychiatry 2014 cited by 111

  15. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder1

    Authors: Ralph Kupka, Lori L. Altshuler, Willem A. Nolen, Trisha Suppes, David A. Luckenbaugh, Gabriele S. Leverich, Mark A. Frye, Paul E. Keck, Susan L. McElroy, Heinz Grunze, Robert M Post - Bipolar Disorders 2007 cited by 391

  16. Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression

    Authors: Minkyung Park, Laura Newman, Philip W. Gold, David A. Luckenbaugh, Peixiong Yuan, Rodrigo Machado‐Vieira, Carlos A. Zarate - Journal of Psychiatric Research 2016 cited by 88

  17. Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion

    Authors: Steven Pennybaker, Mark J. Niciu, David A. Luckenbaugh, Carlos A. Zarate - Journal of Affective Disorders 2016 cited by 76

  18. A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate Channel Blocker in Major Depression

    Authors: Carlos A. Zarate, Daniel C. Mathews, Lobna Ibrahim, Jose Franco Chaves, Craig A. Marquardt, Immaculata Ukoh, Libby Jolkovsky, Nancy E. Brutsché, Mark A. Smith, David A. Luckenbaugh - Biological Psychiatry 2012 cited by 253

  19. A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder

    Authors: Lobna Ibrahim, Nancy Diazgranados, Libby Jolkovsky, Nancy E. Brutsché, David A. Luckenbaugh, W. Joseph Herring, William Z. Potter, Carlos A. Zarate - Journal of Clinical Psychopharmacology 2012 cited by 215

  20. Clinical Predictors of Ketamine Response in Treatment-Resistant Major Depression

    Authors: Mark J. Niciu, David A. Luckenbaugh, Dawn F. Ionescu, Sara Guevara, Rodrigo Machado‐Vieira, Erica M. Richards, Nancy E. Brutsché, Neal M. Nolan, Carlos A. Zarate - The Journal of Clinical Psychiatry 2014 cited by 165

  21. Brain-Derived Neurotrophic Factor and Initial Antidepressant Response to anN-Methyl-D-Aspartate Antagonist

    Authors: Rodrigo Machado‐Vieira, Peixiong Yuan, Nancy E. Brutsché, Nancy Diazgranados, David A. Luckenbaugh, Husseini K. Manji, Carlos A. Zarate - The Journal of Clinical Psychiatry 2009 cited by 153

  22. Validation of digital spiral analysis as outcome parameter for clinical trials in essential tremor

    Authors: Dietrich Haubenberger, Daniel Kalowitz, Fatta B. Nahab, Camilo Toro, Dominic Ippolito, David A. Luckenbaugh, Loretta Wittevrongel, Mark Hallett - Movement Disorders 2011 cited by 117

  23. Repetitive TMS combined with exposure therapy for PTSD: A preliminary study

    Authors: Elizabeth Osuch, Brenda E. Benson, David A. Luckenbaugh, Marilla Geraci, Robert M. Post, Una D. McCann - Journal of Anxiety Disorders 2008 cited by 178

  24. Intermittent theta-burst transcranial magnetic stimulation for treatment of Parkinson disease

    Authors: David Benninger, Brian D. Berman, Elise Houdayer, Natassja Pal, David A. Luckenbaugh, Logan Schneider, Suci Miranda, Mark Hallett - Neurology 2011 cited by 173